Literature DB >> 22545495

[Risk of cutaneous squamous cell carcinomas: the role of clinical and pathological reports].

Annemay Chollet1, Daniel Hohl, Patrick Perrier.   

Abstract

The history of most cutaneous squamous cell carcinomas (CSCC) is limited to the skin. However, about 4% of these malignancies are at risk of metastasis and can be life-threatening. This risk is determined by clinical and histological elements which are individually recognized, but so far staging systems allow us neither to assess a risk score, nor to adopt a standardized therapeutical approach. This article reviews prognostic factors for CSCC, and underlines the need for the clinician to have all clinical and histological elements available, in order to try to define the best therapeutical strategy for each case, following up-to-date recommendations.

Entities:  

Mesh:

Year:  2012        PMID: 22545495

Source DB:  PubMed          Journal:  Rev Med Suisse        ISSN: 1660-9379


  4 in total

1.  FT-IR Spectroscopy Study in Early Diagnosis of Skin Cancer.

Authors:  Maria Kyriakidou; Jane Anastassopoulou; Aristeidis Tsakiris; Maria Koui; Theophile Theophanides
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

2.  Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma.

Authors:  Julien Schaller; Hélène Maby-El Hajjami; Sylvie Rusakiewicz; Kalliopi Ioannidou; Nathalie Piazzon; Alexandra Miles; Déla Golshayan; Olivier Gaide; Daniel Hohl; Daniel E Speiser; Karin Schaeuble
Journal:  Oncotarget       Date:  2021-03-30

3.  Extrinsic aging: UV-mediated skin carcinogenesis.

Authors:  Fragkiski Tsatsou; Myrto Trakatelli; Aikaterini Patsatsi; Konstantinos Kalokasidis; Dimitrios Sotiriadis
Journal:  Dermatoendocrinol       Date:  2012-07-01

4.  Multiple Pulmonary Metastases of Cutaneous Squamous Cell Carcinoma.

Authors:  Hisako Kushima; Hiroshi Ishii; Rikako Shima; Yoshiaki Kinoshita; Kentaro Watanabe; Masaki Fujita
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.